Local Antibiotic Delivery for Community Acquired Pneumonia - Pilot study (LANDCAP1)

Conditions

Community-acquired pneumonia

Brief summary

Proportion of patients with a drop in FEV1 of 20% or 300mL one hour following the first inhalation.

Detailed description

Proportion of patients with a drop in FEV1 of 20% or 300mL from baseline to day 4 or discharge, whichever comes first., CRP on day 4 higher than on any day from 1 to 3 including baseline., MAP ≤ 65 OR respiratory frequency > 25 OR pulse > 100 OR needing supplemental oxygen (1-4 of these fulfilled) on day 4., PCT on day 4 higher than baseline., Temperature ≥ 38.0 °C on day 4., Patient reported outcome measurements: Changes in Visual Analogue Scales for dyspnoea, cough and fatigue from baseline to day 4.

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGQuinsair 240 mg nebuliser solution

DRUGSODIUM CHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients with a drop in FEV1 of 20% or 300mL one hour following the first inhalation.	—

Secondary

Measure	Time frame
Proportion of patients with a drop in FEV1 of 20% or 300mL from baseline to day 4 or discharge, whichever comes first., CRP on day 4 higher than on any day from 1 to 3 including baseline., MAP ≤ 65 OR respiratory frequency > 25 OR pulse > 100 OR needing supplemental oxygen (1-4 of these fulfilled) on day 4., PCT on day 4 higher than baseline., Temperature ≥ 38.0 °C on day 4., Patient reported outcome measurements: Changes in Visual Analogue Scales for dyspnoea, cough and fatigue from baseline to day 4.	—

Measure

Time frame

Proportion of patients with a drop in FEV1 of 20% or 300mL from baseline to day 4 or discharge, whichever comes first., CRP on day 4 higher than on any day from 1 to 3 including baseline., MAP ≤ 65 OR respiratory frequency > 25 OR pulse > 100 OR needing supplemental oxygen (1-4 of these fulfilled) on day 4., PCT on day 4 higher than baseline., Temperature ≥ 38.0 °C on day 4., Patient reported outcome measurements: Changes in Visual Analogue Scales for dyspnoea, cough and fatigue from baseline to day 4.

—

Countries

Denmark

Outcome results

None listed